PE20061354A1 - Compuestos 2-amino-4-oxobutil como inhibidores de la dipeptidil peptidas-iv - Google Patents

Compuestos 2-amino-4-oxobutil como inhibidores de la dipeptidil peptidas-iv

Info

Publication number
PE20061354A1
PE20061354A1 PE2006000351A PE2006000351A PE20061354A1 PE 20061354 A1 PE20061354 A1 PE 20061354A1 PE 2006000351 A PE2006000351 A PE 2006000351A PE 2006000351 A PE2006000351 A PE 2006000351A PE 20061354 A1 PE20061354 A1 PE 20061354A1
Authority
PE
Peru
Prior art keywords
nil
amino
dihydro
compounds
oxobutil
Prior art date
Application number
PE2006000351A
Other languages
English (en)
Inventor
Chang-Seok Lee
Jong Sung Koh
Geun Tae Kim
Sang Yong Hong
Min-Jung Kim
Dongchul Lim
Hee Oon Han
Oh Kwan Kwon
Dong-Jun Yeo
Zi-Ho Yeom
Ji Young Kim
Gwong-Cheung Hur
Sung Ho Kim
Seong Cheol Bu
Hye Jin Kim
Hyen Joo Yim
Sungsub Kim
Kyoung-Hee Kim
Ki Dong Koo
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of PE20061354A1 publication Critical patent/PE20061354A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

SE REFIERE A COMPUESTOS 2-AMINO-4-OXOBUTIL DE FORMULA (I), EN DONDE A ES i) EN DONDE R1 ES H O ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO; X ES C O N; ii) 3-(R2)-4,5-DIHIDRO-7H-ISOOXAZOL[3,4-c]PIRIDI-6-NIL; iii) 3,4-DIHIDRO-1H-ISOQUINOLI-1-NIL; iv) 2-(R3)-4-(R3')-5,8-DIHIDROPIRIDO[3,4-d]-PIRIMIDI-7-NIL; v) 2-()-6,7-DIHIDRO[1,3]TIAZOLO[4,5-C]PIRIDI-5(4H)-NIL; ENTRE OTROS y B ES UN GRUPO DE FORMULA 8); 9); 10) O 11). SON COMPUESTOS PREFERIDOS: 3-[2S-AMINO-4-OXO-4-(3-TRIFLUOROMETIL-5,6-DIHIDRO-8H-[1,2,4]TRIAZOLO[4,3-a]PIRAZI-7-NIL)-BUTIL]-OXAZOLIDI-2-NONA, 1-[2S-AMINO-4-OXO-4-(3-TRIFLUOROMETIL-5,6-DIHIDRO-8H-[1,2,4]TRIAZOLO[4,3-a]PIRAZI-7-NIL)-BUTIL]-PIPERIDI-2-NONA, 1-{(2S)-2-AMINO-4-OXO-4-[2-FENIL-4-(TRIFLUOROMETIL)-5,8-DIHIDROPIRIDO[3,4-d]PIRIMIDI-7(6H)-NIL]BUTIL}-5,5-DIFLUOROPIPERIDI-2-NONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA DIPEPTIDIL PEPTIDASA-IV (DPP-IV), POR LO QUE SON UTILES EN EL TRATAMIENTO DE DIABETES MELLITUS O LA OBESIDAD
PE2006000351A 2005-04-01 2006-03-30 Compuestos 2-amino-4-oxobutil como inhibidores de la dipeptidil peptidas-iv PE20061354A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20050027756 2005-04-01
KR20050053761 2005-06-22
KR20050085980 2005-09-15
KR20050122361 2005-12-13

Publications (1)

Publication Number Publication Date
PE20061354A1 true PE20061354A1 (es) 2007-01-02

Family

ID=37053586

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000351A PE20061354A1 (es) 2005-04-01 2006-03-30 Compuestos 2-amino-4-oxobutil como inhibidores de la dipeptidil peptidas-iv

Country Status (28)

Country Link
US (1) US7879848B2 (es)
EP (1) EP1863812B1 (es)
JP (1) JP4977685B2 (es)
KR (3) KR100776623B1 (es)
CN (1) CN101151265B (es)
AR (1) AR053195A1 (es)
AT (1) ATE473976T1 (es)
AU (1) AU2006229520B2 (es)
BR (1) BRPI0609424B8 (es)
CA (1) CA2602248C (es)
DE (1) DE602006015443D1 (es)
DK (1) DK1863812T3 (es)
EA (1) EA012591B1 (es)
ES (1) ES2349178T3 (es)
IL (1) IL185479A (es)
MA (1) MA29586B1 (es)
MX (1) MX2007012175A (es)
MY (1) MY150102A (es)
NZ (1) NZ560789A (es)
PE (1) PE20061354A1 (es)
PL (1) PL1863812T3 (es)
PT (1) PT1863812E (es)
SI (1) SI1863812T1 (es)
TW (1) TWI357902B (es)
UA (1) UA89396C2 (es)
UY (1) UY29448A1 (es)
WO (1) WO2006104356A1 (es)
ZA (1) ZA200708304B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
KR20120030570A (ko) 2007-04-03 2012-03-28 미쓰비시 타나베 파마 코퍼레이션 디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용
CN101357922B (zh) * 2007-08-02 2011-05-18 山东轩竹医药科技有限公司 新的dpp-iv抑制剂
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2227461A1 (en) * 2007-12-05 2010-09-15 AstraZeneca AB (Publ) New compounds iii
EP2220086A4 (en) * 2007-12-21 2010-12-22 Lg Life Sciences Ltd DIPEPTIDYLPEPTIDASE IV-INHIBITABLE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFOR AS ACTIVE AGENT
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101486689B (zh) * 2008-01-18 2011-08-10 山东轩竹医药科技有限公司 具有磺酰胺基甲酰胺哌嗪结构的dpp-iv抑制剂
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
JO2870B1 (en) * 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20110136850A (ko) * 2009-03-13 2011-12-21 썬 케미칼 비.브이. 에너지-경화성 조성물에 유용한 사이클릭 카바메이트 화합물
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8871760B2 (en) * 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102260265B (zh) * 2010-05-24 2015-09-02 上海阳帆医药科技有限公司 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2810393C (en) * 2010-09-03 2016-04-12 Lg Life Sciences Ltd. Method of preparing 3-amino-4-(2-oxo-piperidin-1-yl)-butyric acid derivative for synthesizing medicament
TWI519533B (zh) * 2010-11-01 2016-02-01 Ｌｇ生命科學有限公司 １－｛（２Ｓ）－２－胺基－４－［２，４－雙（三氟甲基）－５，８－二氫吡啶并［３，４－ｄ］嘧啶－７（６Ｈ）－基］－４－側氧丁基｝－５，５－二氟哌啶－２－酮酒石酸鹽之水合物
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
CN105085528A (zh) * 2014-05-15 2015-11-25 成都贝斯凯瑞生物科技有限公司 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
BR112018017077A2 (pt) 2016-02-23 2018-12-26 Univ Indiana Res & Tech Corp terapias de combinação para tratamento de atrofia muscular espinhal
KR102068754B1 (ko) * 2017-04-20 2020-01-21 주식회사 엘지화학 의약품 합성용 중간체 화합물의 제조 방법
RU2741389C1 (ru) * 2017-11-16 2021-01-25 ЭлДжи КЕМ, ЛТД. Способ получения промежуточного соединения для синтеза лекарственного средства
CN108191647B (zh) * 2018-02-22 2020-09-29 江苏尚莱特医药化工材料有限公司 2,2-二氟二羧酸二烷基酯的合成方法
CN111537622B (zh) * 2019-11-29 2021-11-26 杭州华东医药集团新药研究院有限公司 一种度格列汀及其盐的杂质的检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
WO2003057144A2 (en) 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
EP1490335B1 (en) 2002-03-25 2007-09-19 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2483843A1 (en) * 2002-04-29 2003-11-13 Merck & Co. Inc. Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
DE60330485D1 (de) * 2002-07-15 2010-01-21 Merck & Co Inc Zur behandlung von diabetes
JP2004285325A (ja) * 2002-12-17 2004-10-14 Fuji Photo Film Co Ltd パターン形成方法及び物質付着パターン材料
JP4504924B2 (ja) * 2002-12-20 2010-07-14 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
US7265128B2 (en) * 2003-01-17 2007-09-04 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2513684A1 (en) * 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20090209491A1 (en) 2004-02-23 2009-08-20 Trustees Of Tufts College Lactams as conformationally constrained peptidomimetic inhibitors
US7291427B2 (en) * 2004-03-19 2007-11-06 Fujifilm Corporation Surface graft material, conductive pattern material, and production method thereof
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
DE102005016170A1 (de) * 2005-04-07 2006-10-12 Grünenthal GmbH 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
KR20080015102A (ko) * 2005-05-10 2008-02-18 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
US20090176825A1 (en) * 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
CA2712265A1 (en) * 2008-01-17 2009-07-23 Gruenenthal Gmbh Substituted sulfonamide derivatives

Also Published As

Publication number Publication date
ATE473976T1 (de) 2010-07-15
CA2602248C (en) 2011-06-28
UA89396C2 (ru) 2010-01-25
AU2006229520B2 (en) 2010-07-29
US7879848B2 (en) 2011-02-01
DK1863812T3 (da) 2010-10-18
BRPI0609424A2 (pt) 2010-03-30
IL185479A0 (en) 2008-01-06
DE602006015443D1 (de) 2010-08-26
EP1863812B1 (en) 2010-07-14
JP2008534581A (ja) 2008-08-28
US20080188471A1 (en) 2008-08-07
NZ560789A (en) 2009-11-27
UY29448A1 (es) 2006-10-31
KR100794184B1 (ko) 2008-01-11
MY150102A (en) 2013-11-29
KR20070094714A (ko) 2007-09-21
EP1863812A4 (en) 2009-06-24
CA2602248A1 (en) 2006-10-05
KR100776623B1 (ko) 2007-11-15
AR053195A1 (es) 2007-04-25
ZA200708304B (en) 2008-11-26
SI1863812T1 (sl) 2010-11-30
IL185479A (en) 2013-08-29
CN101151265A (zh) 2008-03-26
WO2006104356A1 (en) 2006-10-05
KR100830902B1 (ko) 2008-05-22
EP1863812A1 (en) 2007-12-12
TWI357902B (en) 2012-02-11
KR20060105609A (ko) 2006-10-11
BRPI0609424B8 (pt) 2021-05-25
CN101151265B (zh) 2012-11-28
ES2349178T3 (es) 2010-12-28
KR20070098774A (ko) 2007-10-05
PT1863812E (pt) 2010-08-04
PL1863812T3 (pl) 2011-02-28
MA29586B1 (fr) 2008-07-01
AU2006229520A1 (en) 2006-10-05
BRPI0609424B1 (pt) 2021-01-26
TW200724542A (en) 2007-07-01
EA012591B1 (ru) 2009-10-30
MX2007012175A (es) 2007-11-21
EA200701854A1 (ru) 2008-02-28
JP4977685B2 (ja) 2012-07-18

Similar Documents

Publication Publication Date Title
PE20061354A1 (es) Compuestos 2-amino-4-oxobutil como inhibidores de la dipeptidil peptidas-iv
PE20060316A1 (es) Derivados de prolina como inhibidores de dipeptidil peptidasa-iv
PE20071104A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv (dpp-4)
PE20050696A1 (es) SAL DIHIDROGENOFOSFATO DE 4-OXO-4-[3-(TRIFLUOROMETIL)-5,6-DIHIDRO[1,2,4]TRIAZOLO[4,3-a]PIRAZIN-7(8H)-IL]-1-(2,4,5-TRIFLUOROFENIL)BUTAN-2-AMINA COMO INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA IV
PE20070367A1 (es) Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa
PE20030654A1 (es) Butanoil-5,6,7,8-tetrahidro (imidazo o triazo) piracinas como inhibidores de dipeptidil peptidasa iv
PE20091353A1 (es) Nuevos compuestos heterociclicos
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20110944A1 (es) DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
WO2007035198A3 (en) Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
PE20110235A1 (es) Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20060437A1 (es) COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
AR070526A1 (es) Derivados de urea de benzomorfanos y estructuras relacionadas, una composicion farmaceutica que incluye al compuesto y un procedimiento de preparacion del mismo
PE20121150A1 (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
PE20080139A1 (es) Compuestos de pirrolotriazina anilina como inhibidores de cinasa
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20091211A1 (es) Derivados de pirazolopirimidina como moduladores de pde9a
PE20061424A1 (es) Compuestos triciclicos de base 1,6-dihidro-1-3,5,6-tetraaza-as-indaceno y composiciones farmaceuticas que comprenden los mismos
PE20110222A1 (es) Inhibidores de dipeptidilpeptidasa iv
PE20081159A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
PE20040197A1 (es) Pirazolopiridinas sustituidas con carbamato
PE20120209A1 (es) DERIVADOS DE IMIDAZO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA O PIRIMIDO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
PE20081377A1 (es) Compuestos de tiazol pirazolopirimidina
PE20070793A1 (es) Compuestos triciclicos que contienen nitrogeno como agentes antibacterianos

Legal Events

Date Code Title Description
FG Grant, registration